Abec‑L (Abacavir + Lamivudine Tablets) is a single daily tablet combining two NRTIs: abacavir and lamivudine. This fixed-dose regimen helps suppress HIV‑1 reverse transcriptase activity, reduce viral replication, and support immune system recovery, while simplifying treatment under physician guidance.
Select options
This product has multiple variants. The options may be chosen on the product page
Atazor‑R (Atazanavir 300 mg + Ritonavir 100 mg Tablets) combines atazanavir and ritonavir in a fixed-dose form. Ritonavir acts as a pharmacokinetic booster, enhancing atazanavir absorption and plasma levels, which helps simplify once-daily dosing. It offers strong HIV‑1 protease inhibition and immune support under medical supervision.
Select options
This product has multiple variants. The options may be chosen on the product page
Tenvir‑L 300 mg/300 mg (Tenofovir + Lamivudine Tablets) offers a potent dual NRTI regimen used in HIV‑1 treatment. This fixed‑dose tablet combines tenofovir disoproxil fumarate and lamivudine to suppress viral replication, support immune function, and simplify therapy adherence under medical supervision.
Select options
This product has multiple variants. The options may be chosen on the product page
Zepdon 400 mg (Raltegravir Tablets) is a high-potency integrase strand transfer inhibitor used in combination antiretroviral therapy to prevent HIV‑1 DNA integration into host cells. Administered orally once or twice daily depending on regimen, Zepdon supports viral suppression and CD4 count recovery with a strong resistance barrier under clinical supervision.
Select options
This product has multiple variants. The options may be chosen on the product page
End of content
End of content
Join our newsletter and get 50% off your first order
Subscribe to our newsletter and get the latest trending products and offers updates.
Wait! before you leave…
We have something special for you
Use above code to get 20% off for your first order when checkout. Don't miss it.
In order to provide you a personalized shopping experience, our site uses cookies. By continuing to use this site, you are agreeing to our cookie policy.